目的 探討華蟾素膠囊聯(lián)合注射用吡柔比星治療晚期乳腺癌的臨床療效。方法 選取錦州醫(yī)科大學(xué)附屬第一醫(yī)院在2015年10月—2017年10月接收的乳晚期腺癌患者120例作為研究對象，將所有患者隨機(jī)分為對照組和治療組，每組各60例。對照組靜脈注射注射用吡柔比星50 mg/m²，1次/d；治療組在對照組治療的基礎(chǔ)上口服華蟾素膠囊，4粒/次，3次/d。4周為1個(gè)療程，兩組患者均持續(xù)治療2個(gè)療程。觀察兩組患者的臨床療效，同時(shí)比較治療前后兩組患者生活質(zhì)量評(píng)分、腫瘤標(biāo)志物水平、副作用、復(fù)發(fā)率和生存率。結(jié)果 治療組患者客觀緩解率（56.67%）顯著高于對照組患者客觀緩解率（46.67%），兩組差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；治療組患者臨床控制率（78.33%）顯著高于對照組患者臨床控制率（68.33%），兩組差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者生理狀態(tài)評(píng)分、心理狀態(tài)評(píng)分、軀體功能評(píng)分、社會(huì)功能評(píng)分均顯著升高，兩組差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；并且治療組患者生活質(zhì)量評(píng)分顯著高于對照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者糖類抗原125（CA125）、糖類抗原153（CA153）和癌胚抗原（CEA）水平均顯著降低，差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；并且治療組腫瘤標(biāo)志物水平顯著高于對照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。對照組患者復(fù)發(fā)率（16.67%）顯著高于治療組患者復(fù)發(fā)率（5.00%），兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療組患者生存率（81.67%）顯著高于對照組患者生存率（58.33%），兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 華蟾素膠囊聯(lián)合注射用吡柔比星治療晚期乳腺癌具有較好的臨床療效，顯著改善患者生活質(zhì)量，改善患者相關(guān)腫瘤標(biāo)志物水平，安全性較高，值得臨床推廣。

Objective To investigate the clinical effect of Huachansu Capsules combined with Pirarubicin for injection in treatment of advanced breast cancer. Methods Patients (120 cases) with advanced breast cancer in the First Affiliated Hospital of Jinzhou Medical University from April 2015 to April 2015 were randomly divided into control and treatment groups, and each group had 60 cases. Patients in the control group were iv administered with Pirarubicin for injection 50 mg/m², once daily. Patients in the treatment group were po administered with Huachansu Capsules on the basis of the control group, 4 grains/time, three times daily. One course of treatment had 4 weeks, and patients in two groups were treated for two courses. After treatment, the clinical efficacy was evaluated, and quality of life score, level of tumor markers, side effects, recurrence rate, and survival rate in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 46.67% and 56.67%, and there were differences between two groups (P<0.05). After treatment, the clinical control rate in the control and treatment groups were 68.33% and 78.33%, and there were differences between two groups (P<0.05). After the treatment, the quality of life scores of the two groups, such as physiological state score, psychological state score, physical function score, and social function score were significantly improved, and the difference between the two groups was statistically significant (P<0.05). And the improvement of quality of life score in treatment group was significantly higher than those in control group. After treatment, the levels of CA125, CA153, and CEA of two groups were significantly increased, and the difference was statistically significant (P<0.05). The levels of tumor markers in the treatment group were significantly higher than those in the control group, and the difference was statistically significant (P<0.05). The recurrence rate of control group (16.67%) was significantly higher than that of treatment group (5.00%), and the difference between two groups was statistically significant (P<0.05). The survival rate of treatment group (81.67%) was significantly higher than that of the control group (58.33%), and the difference between the two groups was statistically significant (P<0.05). Conclusion Huachansu Capsules combined with Pirarubicin for injection has good clinical curative effect in treatment of advanced breast cancer, can significantly improve the patients quality of life and levels of tumor markers, which has a certain clinical application value.